ArchiveJanuary 2013

Should Pharma come clean?

#MSBlog: Should pharma companies release clinical data to the public? Nigel Hawkes. Drug companies should release data from all trials of licensed drugs, say MPs. BMJ 2013; 346 doi: The drug industry should be obliged to release in a publicly accessible form all the information it possesses about trials of licensed drugs, the House of Commons Health Committee has said in a new report on the...

Alternative Medicine..safe? But where is the Evidence?

Senders et al. Mind-body medicine for multiple sclerosis: a systematic review. Autoimmune Dis. 2012;2012:567324. doi: 10.1155/2012/567324. Background: Mind-body therapies are used to manage physical and psychological symptoms in many chronic health conditions. Objective: To assess the published evidence for using mind-body techniques for symptom management of multiple sclerosis. Methods. MEDLINE...

Imaging the blood brain barrier

Coisne C, Lyck R, Engelhardt B Live cell imaging techniques to study T cell trafficking across the blood-brain barrier in vitro and in vivo Fluids Barriers CNS. 2013 ;10(1):7. [Epub ahead of print]   BACKGROUND: The central nervous system (CNS) is an immunologically privileged site to which access for circulating immune cells is tightly controlled by the endothelial blood–brain barrier...

Doctors and social media; do we breach any of the guidelines?

“In response to several comments from colleagues regarding my role on this blog. We have sought guidance from the British Medical Association who make the following points in their document on ‘Using social media: practical and ethical guidance for doctors and medical students’.” Key points: Social media can blur the boundary between an individual’s public and professional...

Safety of Steroids for relapses

#MSBlog: How safe and well-tolerated are steroids for acute MS attacks? Shaygannejad et al. Short-Term Safety of Pulse Steroid Therapy in Multiple Sclerosis Relapses. Clin Neuropharmacol. 2013 Jan;36(1):1-3. OBJECTIVE: To determine the short-term safety of high-dose intravenous methylprednisolone in acute attacks of MS. METHOD: In a prospective study, we evaluated the MSers who received high...

Spinal cord stimulation for intractable MS pain

#MSBlog: Although rarely done spinal cord stimulation can have a dramatic response in MSers with intractable central pain. Burkey  & Abla-Yao. Successful treatment of central pain in a multiple sclerosis patient with epidural stimulation of the dorsal root entry zone. Pain Med. 2010 Jan;11(1):127-32. doi: 10.1111/j.1526-4637.2009.00764.x. OBJECTIVE:  This is a report of a...

Bone damage from steroid treatment in MSers

#MSBlog: A previous post, from last year, that explains what avascular necrosis of the hip is! Epub ahead of print: Sahraian et al. Avascular necrosis of the femoral head in multiple sclerosis: report of five patients. Neurol Sci. 2011 Dec 31.  Osteonecrosis (death of bone due to blockage of blood vessels) of the femoral head (top of thigh bone) is a severe complication of...

Research: MCAM a marker of inflammation

Epub: Duan et al. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis.Neuroscience. 2013 Jan  doi:pii: S0306-4522(13)00050-X. 10.1016/j.neuroscience.2013.01.020.  Background: The soluble form of CD146 has been reported to be present in various inflammatory diseases and displays pro-inflammatory properties. However, little is known about sCD146 in multiple sclerosis...

Interferon injections every 2 or 4 weeks: a potential life-line for injectables

BIOGEN IDEC ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF PEGINTERFERON BETA-1A IN MULTIPLE SCLEROSIS Jan. 24, 2013– Biogen Idec (NASDAQ: BIIB) released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE. Results support peginterferon beta-1a as a potential treatment dosed every two weeks or every four weeks for relapsing-remitting...

Biomarker Update Talk: Porto 25 Jan 2013

“As promised; the talk I gave yesterday at the 2nd International Porto Congress of Multiple Sclerosis.”

“The content of my talk should be self-explanatory. The aim of the talk was to make it clinically relevant and to give example of how we are currently using biomarkers in clinical practice.”

Translate

Categories

Recent Posts

Recent Comments

Archives